Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,369 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 16, 2026, 10:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

NCT00396877
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel (SR25990), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 92 Days
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 16, 2026, 10:05 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EMS Providers' Health Initiative Study

NCT05153759
View directory record Official record
Conditions
Shift-work Disorder
Interventions
Meal service
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influenza Antiviral DAS-181-F04 in Healthy Adults

NCT01651494
View directory record Official record
Conditions
Influenza
Interventions
DAS181, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 16, 2026, 10:05 AM EDT
Recruiting No phase listed Observational

Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study

NCT06800105
View directory record Official record
Conditions
Ovary Cancer
Interventions
High fat smoothie
Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epigenetic Effects of a Single Bout of Exercise on Cardiovascular Risk Factors and the Metabolome

NCT05034380
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Cardiovascular Diseases, Acute Exercise
Interventions
Acute exercise
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 16, 2026, 10:05 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

An Efficacy Trial in the Research Area of Gastrointestinal Health & Bloating

NCT05418127
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
Active, Placebo
Dietary Supplement · Other
Lead sponsor
Coconut Goodness Food Products Inc.
Industry
Eligibility
25 Years to 54 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

NCT00866918
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Interventions
Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 16, 2026, 10:05 AM EDT
Terminated Phase 1 Interventional

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

NCT00669890
View directory record Official record
Conditions
Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Gemtuzumab Ozogamicin, Busulfan, Cyclophosphamide, Thymoglobulin, Tacrolimus, Mycophenolate Mofetil, Methotrexate
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention

NCT03895320
View directory record Official record
Conditions
Sexual Behavior, Unprotected Sex, Gonorrhea, Chlamydia, Trichomonas, Sexually Transmitted Diseases, Adolescent Behavior, Self Evaluation
Interventions
Sexual Health Risk Assessment, Sexual Health Score, Sexual Health Messaging, Water SSB Quiz, Water SSB Score, Water SSB Messaging, STI Screening
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
14 Years to 26 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 16, 2026, 10:05 AM EDT
Active, not recruiting Phase 2 Interventional

Rapid Administration Pilot for Infusing Dinutuximab

NCT05421897
View directory record Official record
Conditions
Neuroblastoma
Interventions
Dinutuximab with Chemotherapy
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Withdrawn Phase 2 Interventional

Garlic in Hyperlipidemia Caused by HAART

NCT00029250
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Hyperglycemia
Interventions
Garlic powder standardized to allicin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

NCT02372110
View directory record Official record
Conditions
Anxiety
Interventions
HPA, ANS stimulation, Placebo
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00070018
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
48
States / cities
Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 16, 2026, 10:05 AM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687
View directory record Official record
Conditions
Schizophrenia
Interventions
CTP-692, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Phase 2 Interventional

Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00186849
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Scavenging of Reactive Carbonyl Species by Blueberries in Humans

NCT07873723
View directory record Official record
Conditions
Human Health, Reactive Carbonyl Species, Polyphenols
Interventions
Blueberries, control group
Dietary Supplement
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
25 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 10:05 AM EDT
Completed Not applicable Interventional

A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)

NCT03362151
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Regular pasta, High protein pasta, White rice
Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 16, 2026, 10:05 AM EDT